In the last decade several studies have been performed to evaluate the clinical outcome of implants inserted into grafted maxillae but few focus on maxillae grafted with bone derived from living donors (BDLD). Bactercline® is an anatase derivate which has anti-bacteria proprieties. There are new implant coated with Bactercline®. In January 2010, a 50 year-old female was referred to the Maxillofacial Department of Galeazzi Hospital (Milan, Italy) who had a diagnosis of severely atrophic maxilla which was grafted with BDLD. After 4 months 11 implants were inserted. To evaluate the clinical outcome several variables (i.e. relate to the anatomy, implant, and prosthesis) were investigated. Implant failure and peri-implant bone resorption were considered as predictors of clinical outcome. ANOVA text was used to compare standard to Bactercline® covered implants. The occlusion is stable after 12 months follow-up. No implants were lost. No implant has a crestal bone resorption higher the cut-off value of 1.5 mm. However the mean peri-implant bone resorption was 0.6 ±0.4 mm in 10 Bactercline® coated implants whereas the only standard implant had 0.01 mm of peri-implant bone resorption. No statistical difference was detected (p = 0.282). These preliminary results shown that no adverse effects on osseointegration were present, and no statistically significant differences Test and Control implants after a mean of 12 months follow-up
BACTERCLINE® COATED IMPLANTS INSERTED IN MAXILLA GRAFTED WITH BONE FROM LIVING DONOUR: A CASE REPORT
CARINCI, Francesco;
2011
Abstract
In the last decade several studies have been performed to evaluate the clinical outcome of implants inserted into grafted maxillae but few focus on maxillae grafted with bone derived from living donors (BDLD). Bactercline® is an anatase derivate which has anti-bacteria proprieties. There are new implant coated with Bactercline®. In January 2010, a 50 year-old female was referred to the Maxillofacial Department of Galeazzi Hospital (Milan, Italy) who had a diagnosis of severely atrophic maxilla which was grafted with BDLD. After 4 months 11 implants were inserted. To evaluate the clinical outcome several variables (i.e. relate to the anatomy, implant, and prosthesis) were investigated. Implant failure and peri-implant bone resorption were considered as predictors of clinical outcome. ANOVA text was used to compare standard to Bactercline® covered implants. The occlusion is stable after 12 months follow-up. No implants were lost. No implant has a crestal bone resorption higher the cut-off value of 1.5 mm. However the mean peri-implant bone resorption was 0.6 ±0.4 mm in 10 Bactercline® coated implants whereas the only standard implant had 0.01 mm of peri-implant bone resorption. No statistical difference was detected (p = 0.282). These preliminary results shown that no adverse effects on osseointegration were present, and no statistically significant differences Test and Control implants after a mean of 12 months follow-upI documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
